Blueprint Medicines — Technical Presentation (November 2017)
13 slides from Blueprint Medicines's technical presentation, Nov 13, 2017
Slide 1: Clinical activity of BLU-285, a KIT/PDGFRα inhibitor designed to treat GIST
Clinical activity of BLU-285, a highly potent and selective KIT/PDGFRα inhibitor designed to treat gastrointestinal stromal tumor (GIST) Michael Heinrich1, Robin Jones2, Margaret von Mehren3, Patrick Schöffski4, Sebastian Bauer5, Olivier Mir6, Philippe A. Cassier7, Ferry Eskens8, Hongliang Shi9, Ter
Slide 2: Disclosures
Disclosures 2 BLU-285 is an investigational agent discovered and currently in development by Blueprint Medicines Corporation (Blueprint Medicines) Dr. Michael Heinrich is an investigator for Blueprint Medicines’ ongoing Phase 1 study in unresectable gastrointestinal stromal tumor Dr. Michael Heinric
Slide 3: High kinome selectivity; binds active conformation
3 High kinome selectivity* Binds active conformation BLU-285 1. Evans EK et al. Sci Transl Med. 2017 Nov 1;9(414) *Kinome illustration reproduced courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com) BLU-285 IC50 Imatinib IC50 KIT Exon 11 deletion JM domain mutations 0.6 nM 12 nM KIT Exon
Slide 4: BLU-285 Phase 1 study
4 Advanced GIST (n=46) MTD Part 2 Dose expansion enrolling PDGFR D842V-mutant GIST (n=50) Unresectable GIST after imatinib and ≥1 other TKI (n=50) Part 1 Dose escalation completed Key objectives Part 1: MTD, safety, pharmacokinetics, ctDNA analyses, anti-tumor activity Part 2: response rate, durati
Slide 5: Demography and baseline patient characteristics
Demography and baseline patient characteristics Parameter All patients, N=116 Age (years), median (range) 62 (25–85) n (%) GIST subtype* KIT mutant PDGFR D842 mutant PDGFR Exon 14 (N659K) mutant KIT & PDGFR WT 76 (66) 37 (32) 2 (2) 1 (1) Metastatic disease 107 (92) Largest target lesion size (cm)
Slide 6: BLU-285 pharmacokinetics support once daily dosing and broad mutational coverage
BLU-285 pharmacokinetics support once daily dosing and broad mutational coverage 6 Relatively rapid absorption median Tmax 4–6 hours, dose-proportional exposure and long half-life >24 hours 300 mg selected as RP2D based on safety, PK, anti-tumor activity 0 6 12 18 24 PDx efficacy exposure 300–400 mg
Slide 7: Tumor reduction across multiple KIT genotypes (central radiology review)
Tumor reduction across multiple KIT genotypes (central radiology review) 7 N=30 patients 300 mg (RP2D) – 400 mg (MTD) -70 20 of 30 (67%) patients with tumor shrinkage 50 -10 -20 -40 -50 Maximum reduction: sum of diameter change from baseline (%) -60 -30 0 10 20 30 40 PD SD PR 13 17 11 13 11 13 11 17
Slide 8: Prolonged PFS in heavily pre-treated KIT-mutant GIST
Prolonged PFS in heavily pre-treated KIT-mutant GIST (central radiology review) 8 No approved therapies beyond third-line regorafenib ORR ~0% with imatinib re-treatment in ≥third-line2 Best response (N=30)* Choi Criteria n (%) RECIST 1.1 n (%) PR 16 (53) 5 (17)^ SD 7 (23) 18 (60) DCR (PR+SD) 23 (77)
Slide 9: Remarkable activity in PDGFR D842-mutant GIST
Remarkable activity in PDGFR D842-mutant GIST (central radiology review) 9 31 of 31 (100%) patients with tumor shrinkage D842V D842V D842V D842V D842V D842V D842V D842V D842-843V D842V D842V D842-H845V D842V D842V D842V D842V D842V D842V D842V D842V D842V D842V D842V D842V D842V D842V D842V D842V D
Slide 10: High response rate and prolonged PFS in PDGFR D842-mutant GIST
High response rate and prolonged PFS in PDGFR D842-mutant GIST (central radiology review) 10 *All dose levels included ^PR from C3 to C13, CR at C16, CR pending confirmation †3 pending confirmation ORR ~0% with currently approved agents3,4 Best response (N=31)* Choi Criteria n (%) RECIST 1.1 n (%)
Slide 11: Treatment emergent adverse events ≥20%
Treatment emergent adverse events ≥20% 11 * Consists of multiple similar AEs that have been aggregated into a single category. 42% of patients at 400 mg (MTD), 18% of patients at 300 mg (RP2D). 39 (34%) patients had grade ≥3 treatment-related AEs: anemia (9%), fatigue (7%), hypophosphatemia (4%), na
Slide 12: BLU-285 has potent, clinically important activity in GIST
BLU-285 has potent, clinically important activity in GIST 12 BLU-285 is well-tolerated at the 300 mg RP2D and provides broad mutational coverage Remarkable response rates and prolonged PFS in PDGFRα-driven GIST may support expedited approval path Prolonged PFS in heavily pretreated KIT-driven GIST w
Slide 13: Acknowledgments
Acknowledgments 13 We thank the participating patients, their families, all study co-investigators, and research coordinators at the following institutions: Oregon Health & Sciences University Dana-Farber Cancer Institute Royal Marsden Hospital/Institute for Cancer Research University Hospitals Leuv
Blueprint Medicines — Technical Presentation (November 2017) on 6ix